Valeo Financial Advisors LLC Has $2.96 Million Stock Position in Stryker Corporation $SYK

Valeo Financial Advisors LLC lowered its stake in Stryker Corporation (NYSE:SYK) by 16.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 8,016 shares of the medical technology company’s stock after selling 1,556 shares during the period. Valeo Financial Advisors LLC’s holdings in Stryker were worth $2,963,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of SYK. Mid American Wealth Advisory Group Inc. acquired a new position in shares of Stryker in the 2nd quarter valued at approximately $26,000. Clayton Financial Group LLC bought a new position in Stryker in the third quarter valued at approximately $26,000. Elevation Point Wealth Partners LLC acquired a new position in Stryker during the second quarter valued at approximately $28,000. Sachetta LLC lifted its stake in Stryker by 58.7% during the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after purchasing an additional 27 shares during the last quarter. Finally, Kilter Group LLC acquired a new stake in shares of Stryker in the 2nd quarter valued at $29,000. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Stryker stock opened at $358.19 on Thursday. The business has a 50 day moving average of $359.50 and a 200-day moving average of $372.07. The company has a market capitalization of $136.98 billion, a P/E ratio of 47.07, a P/E/G ratio of 2.27 and a beta of 0.89. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $404.87. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.85 and a quick ratio of 1.13.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Friday, October 31st. The medical technology company reported $3.19 earnings per share for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. The business had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. Stryker had a return on equity of 24.07% and a net margin of 12.07%.Stryker’s quarterly revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the business posted $2.87 earnings per share. On average, equities research analysts predict that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Wednesday, December 31st will be issued a $0.88 dividend. The ex-dividend date is Wednesday, December 31st. This is a boost from Stryker’s previous quarterly dividend of $0.84. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker’s dividend payout ratio (DPR) is currently 46.25%.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 276,173 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the completion of the transaction, the director owned 2,702,108 shares in the company, valued at approximately $954,600,714.24. This trade represents a 9.27% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO William E. Berry, Jr. sold 1,953 shares of the business’s stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $365.49, for a total transaction of $713,801.97. Following the completion of the transaction, the chief accounting officer owned 2,833 shares in the company, valued at $1,035,433.17. This trade represents a 40.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 522,118 shares of company stock valued at $185,381,932. 5.20% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

SYK has been the subject of a number of research analyst reports. Truist Financial lowered their price target on Stryker from $400.00 to $392.00 and set a “hold” rating for the company in a report on Thursday, December 18th. BTIG Research reissued a “buy” rating and set a $410.00 target price on shares of Stryker in a research note on Friday, November 14th. Royal Bank Of Canada reissued an “outperform” rating and issued a $435.00 target price on shares of Stryker in a report on Friday, November 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $448.00 price target on shares of Stryker in a report on Friday, November 14th. Finally, Piper Sandler reissued an “overweight” rating on shares of Stryker in a research note on Tuesday. Twelve equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat, Stryker presently has an average rating of “Moderate Buy” and an average target price of $425.94.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.